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The ruxolitinib effect: understanding 
how molecular pathogenesis and epigenetic 
dysregulation impact therapeutic efficacy 
in myeloproliferative neoplasms
Graeme Greenfield1* , Suzanne McPherson1, Ken Mills1† and Mary Frances McMullin2†
Abstract 
The myeloproliferative neoplasms (MPN), polycythaemia vera (PV), essential thrombocythemia (ET) and primary 
myelofibrosis (PMF) are linked by a propensity to thrombosis formation and a risk of leukaemic transformation. Activa-
tion of cytokine independent signalling through the JAK/STAT cascade is a feature of these disorders. A point muta-
tion in exon 14 of the JAK2 gene resulting in the formation of the JAK2 V617F transcript occurs in 95% of PV patients 
and around 50% of ET and PMF patients driving constitutive activation of the JAK/STAT pathway. Mutations in CALR or 
MPL are present as driving mutations in the majority of remaining ET and PMF patients. Ruxolitinib is a tyrosine kinase 
inhibitor which inhibits JAK1 and JAK2. It is approved for use in intermediate and high risk PMF, and in PV patients 
who are resistant or intolerant to hydroxycarbamide. In randomised controlled trials it has demonstrated efficacy in 
spleen volume reduction and symptom burden reduction with a moderate improvement in overall survival in PMF. In 
PV, there is demonstrated benefit in haematocrit control and spleen volume. Despite these benefits, there is limited 
impact to induce complete haematological remission with normalisation of blood counts, reduce the mutant allele 
burden or reverse bone marrow fibrosis. Clonal evolution has been observed on ruxolitinib therapy and transforma-
tion to acute leukaemia can still occur. This review will concentrate on understanding the clinical and molecular 
effects of ruxolitinib in MPN. We will focus on understanding the limitations of JAK inhibition and the challenges to 
improving therapeutic efficacy in these disorders. We will explore the demonstrated benefits and disadvantages of 
ruxolitinib in the clinic, the role of genomic and clonal variability in pathogenesis and response to JAK inhibition, epi-
genetic changes which impact on response to therapy, the role of DNA damage and the role of inflammation in these 
disorders. Finally, we will summarise the future prospects for improving therapy in MPN in the JAK inhibition era.
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Background
Myeloproliferative diseases were first described by 
Dameshek in the 1950’s by linking high blood counts 
and disease phenotypes [1]. Since then, the World 
Health Organisation (WHO) has defined polycythae-
mia vera (PV), essential thrombocythemia (ET), pri-
mary myelofibrosis (PMF) and pre-fibrotic PMF as 
the most common Philadelphia chromosome negative 
myeloproliferative neoplasms (MPN) [2]. The poly-
clonal proliferation of myeloid cells in normal health 
is replaced by an abnormal monoclonal proliferation 
resulting in an overproduction of red blood cells in PV, 
platelets in ET and bone marrow fibrosis in PMF. There 
are common phenotypic characteristics, with a predis-
position to thromboembolic and haemorrhagic pathol-
ogies and a risk of progression to myelofibrosis (MF) or 
leukaemic/blast phase transformation.
A point mutation in exon 14 of the JAK2 gene result-
ing in the formation of the JAK2 V617F transcript and 
conformational shift of the resulting JH2 pseudo-kinase 
domain of JAK2 drives constitutive activation of the 
JAK/STAT pathway. This is identified in approximately 
95% of PV cases and around 50% of ET and PMF cases 
[3, 4]. The remaining 5% of PV patients are almost 
entirely accounted for by mutations in exon 12 of the 
JAK2 gene. The majority of remaining ET and PMF 
cases have JAK/STAT activation resulting from driving 
mutations in CALR or MPL genes [5–7]. A small num-
ber of ET and PMF cases are “triple negative” [8].
The introduction of targeted JAK inhibition (JAKi) 
within the last decade has brought an element of preci-
sion medicine and an attempt at disease modification 
to the MPN field. Ruxolitinib (RUX) is a JAK1/JAK2 
inhibitor which has been approved by the US Food and 
Drug Agency and European Medicines Agency for the 
treatment of intermediate and high risk MF and second 
line for PV patients resistant or intolerant to hydroxy-
carbamide (HU).
This review will concentrate on understanding the 
molecular aspects and epigenetic dysregulation impact-
ing on the clinical effects of RUX in MPN. Understand-
ing the limitations of JAKi at a genomic and cellular 
level highlight the challenges to improving therapeu-
tic options in MPN. We will explore the demonstrated 
benefits and disadvantages of RUX in the clinic and the 
role that genomic changes, clonal variability and epi-
genetics have in pathogenesis of MPN and response to 
JAKi. We will also consider how JAKi interacts with the 
role of DNA damage and inflammation in these disor-
ders. Improving therapy in MPN in the JAKi era is an 
unmet need and we will summarise future prospects.
Main text
JAK inhibition in the clinic
RUX has demonstrated efficacy in spleen volume 
reduction and symptom burden reduction when com-
pared against best available therapy (BAT) or placebo 
in intermediate or high risk MF [9–14]. There is a rapid 
recurrence of symptoms evident in MF patients on dis-
ease interruption [9]. Improved overall survival (OS) 
was also observed in the initial phase 3 studies. A com-
bined analysis of the COMFORT-I AND COMFORT-
II studies demonstrated a 30% risk reduction of death 
and a significant survival advantage in those originally 
randomised to RUX in comparison to those crossing 
over [15]. However, the nature of early cross-over from 
BAT or placebo to RUX in the control arm and insuffi-
cient power to assess the survival benefit mean that the 
impact on OS has been questioned by some [16, 17]. In 
PV, improved haematocrit control and spleen volume 
reduction have been demonstrated in comparison to 
best available therapy [18–21]. The only randomised 
control trial undertaken comparing RUX to best avail-
able therapy in ET did not show any benefit as second 
line therapy in patients intolerant or resistant to HU 
[22]. An earlier phase 2 study of RUX in ET did sug-
gest an improvement in symptom burden in the same 
second line setting, but did not include a control arm 
[23]. Table 1 summarises the findings of the key clinical 
trials undertaken to date.
The efficacy of RUX is variable across the MPN phe-
notype with clear benefits for selected patients. Despite 
the direct targeting of the JAK/STAT signalling it is 
limited as a true disease modifying therapy. As dem-
onstrated in Table  1 reductions in mutant allele bur-
den are minimal to moderate yet are often sustained 
on therapy. Transformations to both secondary MF and 
acute leukaemia have both been observed on ruxoli-
tinib therapy with no studies with adequate follow-up 
or statistical power to determine if there is any devia-
tion in frequency from this aspect of disease course. 
There is a suggestion of lower rates of thrombosis in 
the RESPONSE trials although statistical power is again 
an issue [20]. In MF, sustained RUX therapy appears 
to improve the odds of stabilisation of bone marrow 
fibrosis and reduce the chance of worsening fibrosis in 
a number of patients but does not bring about any sig-
nificant reversal [24]. Allogeneic haematopoietic stem 
cell transplantation offers the only possibility of dis-
ease modification and cure. However, the majority of 
patients will not be considered suitable for this due to 
the associated toxicities.
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Genomic impacts on pathogenesis and JAK inhibition 
efficacy
Constitutive activation of the JAK/STAT signalling 
pathway is key to the development of the MPN phe-
notype in all mutant backgrounds. Regardless of clini-
cal phenotype or somatic mutation status, all MPN 
patients show a characteristic gene expression signature 
resulting from JAK/STAT activation [8]. JAK2 V617F 
mutations can drive a spectrum of disease across the 
PV, ET or PMF phenotypes through activation of eryth-
ropoietin receptor (EPOR), thrombopoietin recep-
tor (MPL) and granulocyte-colony stimulating factor 
receptor (G-CSFR) receptors present on differing stages 
of a maturing myeloid cell. JAK2 exon 12 mutations 
drive a predominant erythrocytosis possibly through 
predominant activation of EPOR signalling pathways. 
Clonal dominance of homozygosity or heterozygosity 
of JAK2 V617F, the presence and order of acquisition of 
co-operating mutations and additional factors such as 
iron deficiency and gender can impact on the resulting 
phenotype [25]. CALR and MPL mutations result in an 
ET or PMF phenotype through activation of the MPL 
receptor [26]. All drivers appear to be largely mutually 
exclusive of each other although bi-clonal disease can 
occur [27]. JAK2, CALR, MPL mutations are sufficient 
in themselves to produce an MPN phenotype in murine 
models although these are often polyclonal in nature 
thus not entirely representative of a true MPN [28]. 
JAK2 V617F and CALR mutations are detectable in the 
long term haematopoietic stem cell (LT-HSC) popula-
tion and in all maturing stages of the haematopoietic 
hierarchy [6, 29]. This persistence of a MPN stem cell 
population can explain relapse of MF post allogeneic 
transplant. LT-HSC cells within the marrow are critical 
for initiation and maintaining the disease process [30]. 
Yet, these JAK2 V617F LT-HSC population appear to 
exhibit reduced self-renewal and are skewed towards 
expansion of the progenitor pool instead [31]. In 
murine models of JAK2 V617F MPN this defective self-
renewal of LT-HSCs is rescued by acquisition of a con-
current TET2 mutation [32]. Given the heterogeneity in 
normal haematopoietic stem cells, the original bias of 
the stem cell acquiring the driver mutation may impact 
on disease progression and phenotype [33].
A range of genes are repeatedly found to be mutated 
in MPN and across the spectrum of myeloid disorders. 
These co-operating oncogenic mutations found along-
side the driver mutations include genes involved in cell 
signalling pathways (LNK, CBL, NRAS and NF1), epige-
netic regulation (ASXL1, EZH2, TET2, DNMT3A, IDH1 
and IDH2), transcriptional regulation (TP53, RUNX1) 
and mRNA processing (SF3B1, SRSF2, U2AF1, ZRSR2). 
Using targeted next generation sequencing (NGS) of 
104 cancer‐related genes on 197 MPN patients, approxi-
mately 10% of patients had no mutation detectable in 
any of the genes analyzed and 54% had mutations only in 
JAK2 V617F or CALR. The remaining 36% had additional 
mutations detected, other than JAK2 V617F or CALR. 
Most of these were mutations affecting genes implicated 
in epigenetic regulation [27]. Figure 1 shows a chart rep-
resenting the relative proportions of driver mutations 
and additional mutations detectable in PV, ET and PMF 
[34, 35]. These genes may occur concurrently within 
clones containing the driver mutation, in sub-clones 
without the driver mutation and at different levels of the 
haematopoietic cell hierarchy and impact on phenotype 
and prognosis [27].
Understanding the impact of this genomic complex-
ity and clonal evolution on the MPN phenotype, patho-
genesis and response to JAKi is critical to improving our 
therapeutic approach.
JAK2 V617F, CALR and MPL exon 10
At the driver gene level for instance, the presence of the 
JAK2 V617F mutation results in a higher thrombotic risk 
in ET and PMF compared to JAK2 negative cases [36]. 
Gene expression patterns consistent with JAK/STAT acti-
vation are also more evident patients with allele ampli-
fication [8]. Homozygosity or higher JAK2 V617F allele 
burden has been suggested to emphasise the PV pheno-
type with a higher haematocrit and greater rate of fibrotic 
transformation observed [37]. Yet, homozygosity for 
JAK2 V617F is a commonly occurring event in MPN and 
can be seen in patients with a PV, ET or PMF phenotype 
whilst the same is true for heterozygotes. JAK2 V617F is 
also detectable in patients without overt haematological 
malignancy phenotypes, the so termed “clonal haemat-
opoiesis of indeterminate potential” (CHIP). Indeed, esti-
mates of JAK2 mutation prevalence are higher in CHIP 
than in MPN [38, 39]. This is suggestive that additional 
changes are required for a MPN phenotype to develop. 
There is inconclusive evidence that the allele burden of 
JAK2 V617F impacts on thrombosis risk with conflicting 
evidence of effect in a number of studies [40]. A unique 
cohort of patients with splanchnic vein thrombosis and 
underlying JAK2 V617F positive mutant clones tend 
towards a lower allele burden [41]. In CHIP the pres-
ence of mutated JAK2 results in a significantly increased 
coronary artery disease risk despite the absence of the 
MPN blood phenotype [42]. It is therefore clear that the 
presence of mutant JAK2 V617F plays a critical role in 
increasing thrombotic risk. This thrombosis risk appears 
to be mediated in part by viscosity from increased haema-
tocrit, in part by increased binding to endothelial laminin 
as a result of an JAK2 V617F driven activation of Lu/
BCAM [43] and from increased neutrophil extracellular 
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trap formation [44]. It is not clearly related to an increas-
ing burden of JAK2 V617F clonal cells present.
RUX has demonstrated a limited impact on the allele 
burden of mutant JAK2 in the clinical trials to date in 
PV and PMF but not ET. COMFORT-II demonstrated a 
reduction in allele burden of greater than 20% in 38.3% 
of RUX treated MF patients at 168  weeks [14]. In PV, 
post hoc analysis of the RESPONSE trial at 208  weeks 
has shown a clear and progressive reduction in JAK2 
V617F allele burden with continued treatment with aver-
age reductions of around one-third achieved in the RUX 
randomised arm [45]. However, correlations with haema-
tological parameters of disease (haematocrit level, leuco-
cyte count, platelet count) were not observed [45]. This 
therefore provides a challenge to the use of JAK2 allele 
burden reduction as a relevant biomarker of treatment 
success. One small study has suggested patients starting 
with a higher allele burden may benefit the most from 
RUX therapy in MF with a study of 69 patients showing a 
higher probability of spleen response if allele burden was 
greater than 50% at entry [46].
The presence of the CALR driver mutation meanwhile 
appears to offer some protection. Despite the observed 
higher platelet counts in CALR positive ET, there is a 
lower thrombosis risk [47]. Indeed, the use of anti-plate-
let agents in low risk CALR positive ET may cause harm 
rather than provide a benefit [48]. Overall survival is also 
comparatively higher in CALR positive MF [47]. The rate 
of leukaemic transformation in CALR patients was simi-
lar to JAK2 V617F patients in a meta-analysis of twelve 
studies in PMF [49]. The presence of type 1 CALR muta-
tions was prognostically favourable for overall survival 
with regards to type 2 CALR mutations in PMF. However, 
multivariate analysis incorporating additional co-muta-
tions and prognostic scoring systems did not retain this 
association [50]. Patients with triple negative mutation 
status in PMF have a faster rate of disease progression 
and leukaemic transformation and worse overall survival 
than any of the driver mutations [47].
The effect of JAK inhibition with RUX in MF does not 
appear to be affected by the underlying driver muta-
tion. COMFORT-I showed no difference in clinical 
effect between JAK2 V617F positive or negative patients 
[10]. A further exploratory analysis of the COMFORT-
II study showed no difference in the response of CALR 
mutant patients in comparison to the cohort as a whole 
Fig. 1 a This demonstrates the relative proportions of driver gene mutation observed in each MPN phenotype. b This demonstrates the proportion 
of patients with each MPN phenotype with a mutations in a panel of genes commonly mutated in myeloid malignancy. Frequency of mutations 
presented is based on data acquired in by Tefferi et al. [34, 35]
Page 7 of 16Greenfield et al. J Transl Med          (2018) 16:360 
[51]. CALR mutant mice develop an ET phenotype that 
is ameliorated by RUX [52]. Likewise, murine models 
of JAK2 V617F positive MPN show response in spleen 
weight and haematological parameters to the adminis-
tration of RUX [53]. Another JAK2 inhibitor INCB16562 
showed efficacy in a murine model of MPL W515L 
induced thrombocytosis and myelofibrosis [54]. This is 
logical given the activation of the JAK/STAT pathway in 
all mutant backgrounds.
The MPN HSC population appear to escape JAKi with 
limited impact on quantitative reduction in the MPN 
HSC population demonstrated even in in  vitro treat-
ment. This is part of the key to explaining why molecular 
remissions are rarely achieved and why MF patients often 
rebound quickly after discontinuation of these drugs [55].
Co‑operating Mutations and Clonal Evolution
Recurrently mutated co-operating oncogenes have key 
roles in cell signalling pathways, epigenetic regulation, 
transcription regulation and mRNA processing. In PMF, 
the presence of the mutations in the genes ASXL1, EZH2, 
SRSF2 and have were observed to independently predict 
shortened survival in a European cohort of 483 patients 
and validated in an American cohort of 396 patients. 
In both cases ASXL1 retained this prognostic relevance 
when prognostic scoring systems were accounted for. In 
both cohorts.
IDH1/2 and SRSF2 mutations were associated with 
leukaemic transformation whilst ASXL1 was also associ-
ated in the European cohort [56]. TP53 mutations were 
not analysed in that study, however somatic mutations 
with loss of heterozygosity in TP53 was strongly asso-
ciated with progression to a leukaemic blast phase in a 
cohort of 197 patients analysed with next generation 
sequencing. Two or more somatic mutations was associ-
ated with the same negative prognosis [27]. JAK2 V617F 
cooperates with loss of TP53 in a murine model to induce 
blast phase disease. A larger cohort of 797 patients across 
Europe and North America demonstrated a statistically 
significant negative impact on overall survival and leu-
kaemia free survival when two or more of ASXL1, EZH2, 
SRSF2 and IDH1/2 were mutated [57]. There is also evi-
dence of reduced progression free survival following allo-
geneic haematopoietic stem cell transplantation for MF 
patients carrying ASXL1 and IDH1/2 at time of trans-
plantation [58].
Some genes are strongly associated with particular 
MPN phenotypes, for example, mutated ASXL1 is docu-
mented in around 38% of PMF patients and a much lower 
percentage of other MPNs [59]. Genes involved in splic-
ing are more commonly mutated in PMF [26, 60]. Oth-
ers, for example, IKZF1 are almost exclusively identified 
in blast phase disease [61]. The majority of PV and ET 
patients possess only one identified mutation in a driver 
gene whilst a much higher number of PMF patients have 
multiple somatic mutations. This is suggestive that acqui-
sition of particular mutations distorts the equilibrium 
in favor of a particular phenotype. It has been suggested 
that the acquisition of co-operating mutations promotes 
a shift towards dysplasia from proliferation and therefore 
PMF could be considered as an additional MPN/MDS 
overlap syndrome [26].
TET2 is commonly mutated in the MPNs and myeloid 
malignancy in general but shows no particular pheno-
typic bias. It was suggested in one study to confer a poor 
risk prognosis for overall survival and blast crisis trans-
formation [27]. It is also frequently detectable in CHIP 
[62]. Timing of acquisition of this mutation appears to 
play a key role in the resulting disease phenotype. TET2 
first cells have a proliferation advantage at the haemat-
opoietic stem cell (HSC) level but do not result in excess 
production of mature megakaryocytes or erythroid cells 
until acquisition of a concurrent JAK2 V617F mutation. 
Cells acquiring the JAK2 V617F mutation first do not 
expand at the HSC level but can produce excess numbers 
of erythroid and megakaryocyte cells through prolifera-
tion of progenitors. Expansion is enhanced by subsequent 
acquisition of the TET2 mutation. These JAK2 V617F 
first cells appear to favour a polycythaemia phenotype, 
with an increased risk of thrombosis in the patient group 
whilst the transcriptional profile of the cells was signifi-
cantly altered dependent on the first acquired mutation 
[63]. In contrast “TET2 first” cells promote an ET phe-
notype. Greater than 70% of MF patients with EZH2 
mutations also harbored ASXL1 mutations in one study. 
These two events were observed in the earliest multipo-
tent HSC population. Acquisition of these mutations in 
this context appears to have preceded the acquisition of 
JAK2, CALR or MPL mutations in many cases [59]. The 
order of genomic event acquisition therefore appears to 
be a key feature in determining the subgroup of MPN, 
with each event potentially providing different selective 
advantages at varying stages of the hematopoietic hierar-
chy and resulting in a different biological outcome.
This resultant changing genomic landscape and acqui-
sition of new mutations allows for the evolution of the 
clonal cell populations over time. In the chronic phase of 
disease this appears to be a very slow process with only 
two new mutations detected during follow-up equiva-
lent to 133 patient years in one study across MPN [27]. 
Dominance can then established by one clone whilst oth-
ers may disappear over time. Co-operating mutations 
may occur alongside the driver mutations or in separate 
clones. Recent work has demonstrated the accumulation 
of low burden of TP53 mutant clones associated particu-
larly with ageing over the course of chronic MPN. This 
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has demonstrated that multiple variants of these TP53 
may exist concurrently [64]. The clonal landscape may 
also vary at different points of the haematopoietic hierar-
chy [63]. The most devastating result of clonal evolution 
is the selection and expansion of a clone resulting in blast 
phase of disease. The leukaemic clone may not even con-
tain the original driver mutation and patients with TP53 
mutations may develop leukaemic clones expressing wild 
type TP53 [64, 65]. The higher prevalence of mutations 
detectable in blast phase disease is suggestive of a higher 
rate of mutation acquisition similar to that seen in blast 
phase CML [66].
There is also interest in the role of germline genomic 
susceptibility factors in MPN. There are cases of familial 
MPN characterised by a number of rare germline muta-
tions including RBBP6. The JAK2 46/1 combination of 
haplotypes is also associated with both JAK2 V617F posi-
tive and MPL positive MPN and is suggested to impact of 
a clonal advantage for any cells acquiring these mutations 
[67]. An in depth review of these germline factors is how-
ever beyond the scope of this article as the impact on the 
effectiveness of RUX has not been clearly evaluated.
We are moving towards a time when molecular mark-
ers will help to provide individualized prognostication 
and reveal a spectrum of phenotype, thrombosis and 
transformation risk [68]. It is in this spectrum of disease 
that the role of JAKi and RUX in particular will need to be 
defined. Molecular data from the initial RUX clinical tri-
als is rather limited in this respect as is shown in Table 1. 
Analysis of the COMFORT-II study in PMF shows that 
when patients were grouped into a high molecular risk 
group according to the presence of mutation(s) in any 
one of ASXL1, EZH2, SRSF2, and IDH1–2 or low molec-
ular risk group as had previously been validated [56], this 
did not affect the likelihood of obtaining a > 35% spleen 
volume reduction or symptomatic improvement [13]. 
However, subsequent analysis of Phase1/2 studies using 
RUX in MF including post PV or post ET-MF suggested 
that the presence of three or more mutations was asso-
ciated with a worse spleen response and shorter time to 
treatment discontinuation [69]. Another recent small 
study suggested that the presence of ASXL1 or EZH2 was 
independently associated with an inferior time to treat-
ment failure on multivariate analysis in a study of 100 MF 
patients treated with RUX or momelotinib [70]. There-
fore, the underlying genomic landscape may affect RUX 
efficacy. In PV, the 208 week evaluation of data from the 
RESPONSE-II trial reported on rates of complete (CMR) 
and partial molecular response (PMR). In the case of 
patients originally randomised to RUX, CMR and PMR 
were possible in patients with ASXL1 and TET2 muta-
tions identified. The prognostic implications of these 
mutations is less clear in PV but again this suggests that 
in particular individuals, that at least in certain individual 
circumstances the effectiveness of RUX is not impacted 
by the presence of these mutations [45]. Of course, the 
definition of CMR or PMR was based on JAK2 V617F 
mutation burden and whether patients with CMR or 
PMR obtained simultaneous reductions in ASXL1 or 
TET2 allele burdens was not reported.
Direct therapeutic targeting of IDH2 using small mol-
ecule inhibition alongside RUX has shown superior effi-
cacy to monotherapy in JAK2 V617F and IDH2 mutant 
murine MPN models and synergistic effects in dual 
mutated primary MPN cells [71]. This highlights the 
potential for direct targeting of mutant cells using per-
sonalised therapy guided by the mutational landscape for 
select patients.
In blast phase, response to conventional systemic 
chemotherapy for acute myeloid leukaemia (AML) 
has a limited efficacy [72]. Median survival is less than 
6 months which can be improved in patients undergoing 
allogeneic stem cell transplantation [73]. However, many 
patients are not fit for this intensive treatment approach. 
RUX monotherapy was effective at improving survival in 
a murine model transplanted with TP53 knockout/JAK2 
V617F positive leukaemic cells but was insufficient to 
induce remissions and was inferior to combination 
therapy with a histone deacetylase inhibitor (HDACi) 
or a Heat shock protein 90 inhibitor [74]. Clinical data 
is sparse but small numbers of patients have shown 
improved responses in combination with intensive chem-
otherapy induction and alongside HDACi [75–77]. In 
MF, patients with an excess of blasts between 5 and 9% 
in bone marrow or peripheral blood demonstrated an 
improved response to RUX which was not seen for those 
with an accelerated phase defined by 10–19% blasts [78]. 
These results suggest that targeted JAKi with RUX may 
have a role in the treatment of blast phase disease but 
optimizing synergy with additional agents is likely to be 
the key to improving therapeutic efficacy in this scenario.
When it comes to clonal evolution understanding the 
impact of RUX is going to be critical. Analysis of phase 
1/2 trials of RUX in MF allowed analysis of molecu-
lar profile from 62 patients at baseline and at discon-
tinuation of RUX therapy. Just over one-third of these 
patients acquired further mutations whilst on therapy. 
These included ASXL1, TET2, EZH2 and TP53 most 
frequently. This clonal evolution was associated with 
shorter survival following RUX discontinuation. Half of 
patients with molecular data available that transformed 
to AML did so on the background of clonal evolution 
during RUX therapy [79]. There have been reports of 
an usually high occurrence of extramedullary leukaemia 
whilst on RUX [80]. However this does not appear to be 
an observed phenomenon in the clinical trial setting or 
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repeatedly reported and therefore may not be significant. 
Monotherapy in malignancy is frequently associated with 
clonal escape and it is not clear whether any selective 
pressure driving this is applied by RUX. Recent work has 
suggested that around 15% of MF patients have demon-
strable Immunoglobulin gene rearrangements (IgR) in 
bone marrow indicative of a B Cell clonal population. 
They further observed an incidence of aggressive B-Cell 
lymphoma in 5.8% of RUX treated patients compared to 
0.36% of patients not exposed to this agent. All of these 
patients had prior detectable IgR. This is suggestive of 
an ability of RUX to select for a lymphoid clone possibly 
through immunosuppressive effect [81]. Whether the 
same may be applicable for myeloid clones is less clear 
but must be carefully evaluated as clinical trials of RUX 
as a front line agent in PV are developed.
Fig. 2 This schematic demonstrates the potential mechanisms of escape from JAK2 inhibition by ruxolitinib. (1) Ineffective JAK inhibition (2) 
Acquired tyrosine kinase domain mutation (3) Heterodimerization of JAK2 with JAK1 or TYK2 (4) Alternative signaling cascade activation (5) External 
cytokine effects (6) Epigentic mechanisms of transcriptional regulation
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Cell signaling pathways
The persistence of MPN clones despite JAKi shows that 
the cells are able to escape the inhibition blockade and 
survive. Figure 2 demonstrates the signaling cascade acti-
vated by constitutive JAK2 activation highlighting a num-
ber of potential mechanisms of escape that have been 
demonstrated.
In many malignancies, resistance to tyrosine kinase 
inhibitor (TKI) therapy occurs on the basis of an acquired 
mutation with a key drug target. This is demonstrated in 
chronic myeloid leukaemia (CML) when acquired resist-
ance to TKIs is often the result of a new mutation within 
the BCR-ABL1 fusion gene. Saturation mutagenesis stud-
ies in murine cell line with RUX have demonstrated the 
emergence of second site mutations within JAK2. These 
mutations conferred resistance to JAKi by a number of 
agents including RUX [82, 83]. However, it is not clear 
that this is a relevant phenomenon which is occurring 
in MPN patients [84] and persisting clones demon-
strate the absence of second site mutations in the pres-
ence of JAKi [85]. This suggests that the dosing of RUX 
is insufficient to exert a selective mutagenesis pressure in 
patients. Genetic deletion of JAK2 in a murine model of 
MPL mutated MPN was more effective than JAKi in ame-
liorating the disease state demonstrating the potential 
benefit of improved JAKi. When persisting JAK2 V617F 
cell lines in RUX were examined it was evident that there 
was reactivation of JAK/STAT signaling. Dimerisation is 
a critical aspect of JAK2 activation and in the presence of 
RUX this can occur as a heterodimer between JAK2 and 
JAK1 or TYK2 resulting in a reactivation of JAK/STAT 
signaling and resistance to JAKi [85]. This is a functional 
mechanism of resistance and appears to be reversible on 
withdrawal of RUX with cells re-sensitizing over a period 
of weeks. It is interesting to note patients may demon-
strate similar responses to RUX re-challenge following 
withdrawal for loss of response [86].
Another possible mechanism of resistance to RUX 
is the recruitment of alternative cell signaling pathways 
continuing to drive the disease phenotype. Constitutive 
activation of JAK/STAT signaling in JAK2 V617F posi-
tive cells is accompanied by activation of the STAT inde-
pendent PI3K or MAPK pathways [4]. CALR mutations 
also activate MAPK signaling [87], however, there does 
appear to be a differential expression profile in MAPK 
and PI3K pathways in CALR mutant ET compared to 
JAK2 V617F mutant ET or PV [88]. These role of these 
pathways in the pathogenesis of MPN and the resistance 
to JAKi is beginning to be elucidated. The PI3K/mTOR 
pathway is critical for the phosphorylation of serine resi-
dues on STAT5b. These phosphorylations on serine-193 
and serine-731 residues were not affected by exposure to 
RUX but were reduced by treatment with PI3K or mTOR 
inhibitors in JAK2 V617 positive cell lines. Combinations 
of RUX with PI3K and mTOR inhibitors was more effi-
cacious in cell lines, primary patient cells and knock in 
mouse models of JAK2 V617F positive MPN [89]. Indeed, 
an mTOR inhibitor everolimus has been trialed in MF 
showing some efficacy in symptom burden control and 
spleen volume reduction [90]. Trials to understand the 
efficacy of RUX in combination with these inhibitors are 
yet to report on efficacy in real world patient samples.
Epigenetic dysregulation beyond genomic mutations 
and cell signaling pathways
Histone modification is a key mechanism of epigenetic 
regulation with n-terminus lysine residues undergoing 
post translational modifications including acetylation, 
methylation and phosphorylation which can enhance or 
repress gene transcription. We have already discussed 
the occurrence of mutations in genes controlling histone 
modification including ASXL1 and EZH2 which are fre-
quently observed in MPN. In murine studies, differential 
distribution of acetylated H3K27 between progenitors in 
MPL W515 mice with an MF phenotype and controls was 
observed. Using a chromatin immunoprecipitation assay 
the active loci marked by acetylated H3K27 were sig-
nificantly associated with Tumor necrosis factor(TNF)/
nuclear factor KB(NF-KB) signaling pathways highlight-
ing a key role of inflammation which will be discussed 
below [91]. Some mechanisms of histone modifica-
tion have been proposed. The mutant JAK2 V617 pro-
tein is able to locate to the nucleus of the cell. In doing 
so, it is able to exert effects through phosphorylation of 
Histone H3 and the arginine methyltransferase PRMT5 
resulting in histone modification and change gene tran-
scription [92, 93]. Over-expression of the transcription 
factor “nuclear factor erythroid 2” (NFE2) occurs in the 
majority of MPN patients. This over-expression results 
in significantly elevated levels of the histone demethylase 
JMJD1C and resultant global reduction of H3K9me1 and 
H3K9me2 levels [94]. There is limited published work 
on the effect of JAKi on histone modifications. We have 
demonstrated modifications to histone methylation at 
lysine 36 on Histone H3 in response to RUX therapy and 
shown that patients with high levels of di and tri methyla-
tion at lysine 4 may have sub-optimal responses to RUX 
therapy [95]. A number of histone deacetylase inhibitors 
have been investigated as therapy in MPN. Only Panobi-
nostat, a pan-deacetylase inhibitor which enhances acet-
ylation at H3 and H4 histones, has been investigated in 
combination with RUX in a phase 2 study. They observed 
greater reductions in splenomegaly than were expected 
for RUX therapy only [96]. Lysine specific demethylase 
1 (LSD1) modifies methylation at histone H3 by removal 
of methyl groups. Inhibition of LSD1 by small molecule 
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is beneficial in murine models of MPN and synergistic 
with RUX in ameliorating the MPN process in mice. JAKi 
alone may be insufficient to overcome effects of prior 
histone modification. The role of combining epigenetic 
manipulation and JAKi needs explored in clinical trials 
[97].
DNA methylation (DNAm) is a further mechanism of 
transcriptional regulation [98]. Changes in DNA meth-
ylation are observed in normal ageing and pathology. 
DNA methyltransferase enzymes (DNMT) act to meth-
ylate cytosine residues at CpG sites silencing transcrip-
tion. Genes involved in this process that are commonly 
mutated in MPN include DNMT3A, TET2 and IDH1/2. 
Samples from MPN patients show aberrant DNA meth-
ylation patterns in comparison to controls and this 
changes again during transformation to blast phase of 
disease [99]. Using an ageing signature based on DNAm 
patterns in key genes [100], we have demonstrated that 
PV patients have a DNAm age which is older than their 
chronological age whilst ET patients tended to have a 
younger DNAm age. Interestingly, following therapeutic 
intervention with RUX, the DNAm age, in both groups, 
moved closer to their actual age [95]. Whether this differ-
ence in DNAm pattern is reflective of a direct influence 
on the MPN phenotype or reflects the actions of other 
cellular processes is unclear but does however demon-
strate another feature of epigenetic dysregulation in these 
pathologies.
DNAm and histone modification represent pre-tran-
scriptional mechanisms of control. Increases or decreases 
in gene transcription levels may be further modified by 
post-transcriptional or post-translational modification 
which may impact on the resulting proteome and ulti-
mately the impact on the cell processes. Quantitative 
mass spectrometry has shown differences in the make-
up of a small proportion of the proteome across different 
MPN phenotypes and mutational backgrounds. Proteins 
in the RAS GTPase and oxidative stress pathways were 
identified as differentially expressed. CALR was noted to 
be over-expressed in JAK2 V617F positive backgrounds 
in comparison to wild type backgrounds suggesting that 
the presence of mutant JAK2 may be able to impact on 
wild type CALR expression which may impact on cellu-
lar signalling impacting on phenotype [101]. This CALR 
overexpression could be ameliorated by JAKi in murine 
cell line culture [101]. To our knowledge, there has been 
no data on the effect of RUX or JAKi on the proteome of 
treated patients.
DNA damage
Given the propensity of MPN cells to acquire multi-
ple genomic aberrations, a number of efforts to under-
stand the role of DNA damage accumulation and repair 
mechanisms have been undertaken. A number of mecha-
nisms linking genome instability have been proposed. 
Activation of JAK2 V617 has been shown to stimulate 
increased homologous recombination activity and can 
result in chromosome centrosome abnormalities and an 
increased rate of mutagenesis in  vitro [102]. This may 
promote a loss of heterozygosity of JAK2. PI3K depend-
ent signalling results in replication fork stalling and 
activation of the intra- S phase cell cycle checkpoint. 
The latter effect was only observed in PV erythroblasts 
and not in ET erythroblasts [103]. Reactive oxygen spe-
cies appear to play a key role in the excess accumula-
tion of double strand DNA breaks (DSBs) that have been 
observed in MPN cells [104, 105]. This was accompanied 
by avoidance of usual apoptotic mechanisms in response 
to DSBs and may help to explain the accumulation of 
additional mutations evident in many MPN cells [104]. 
Downregulation of NHE1/BCL-xl pro-apoptotic path-
ways via PI3K mediated inactivation of FOXO3A allows 
inappropriate cell survival despite DNA damage accu-
mulation. This mechanism appears to be differentially 
present in stem cells in comparison to progenitors [106]. 
Anti-oxidative therapies were effective in reducing the 
number of DSBs acquired in JAK2 V617F positive mouse 
model and in reducing the progression of the MPN phe-
notype demonstrating the importance of this genomic 
instability in pathogenesis [104]. JAK2 V617F expression 
can negatively regulate p53 via degradation by increased 
levels of MDM2 thus impacting on the critical role p53 
plays in the DNA damage response [107]. Downregula-
tion of DNA repair pathways mediated by BRCA1 and 
ATM has been demonstrated in CALR mutants by gene 
expression profiling [88]. RUX has been demonstrated to 
inhibit BRCA-mediated homologous recombination and 
DNA—dependent protein kinase-mediated non homolo-
gous end joining. This leads to an accumulation of DSBs 
which lead to synthetic lethality in cell line cultures, pri-
mary MPN samples in vitro and xenograft models when 
combined with poly-ADP-ribose polymerase (PARP) 
inhibitors [105]. Given that RUX is poor at inducing 
apoptotic pathways [108], this reduction in the DNA 
repair mechanisms in cells that are prone to increased 
DNA damage may potentially allow for clonal selection 
in monotherapy highlighting the critical need for vigi-
lance for clonal evolution in front line RUX trials.
Inflammation
Neoplastic disease has been linked to inflammation in 
many ways, including, as a driver of malignant change, 
sustaining the disease or resulting from the neoplas-
tic cells. Levels of circulating cytokines are higher in 
MPN patients. A number of studies have demonstrated 
prognostic value for IL-8, IL-2R, IL-12, IL-15 and high 
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sensitivity C reactive protein (CRP) levels in MF [109, 
110]. Both mature and progenitor cells demonstrate an 
aberrant cytokine production pattern with differences 
evident between the two [111]. Cytokine profiles are also 
different between the MPN phenotypes with higher levels 
seen during transformation of disease to secondary MF 
or AML [112]. In the general population, inflammation is 
linked to thrombosis and increasing high sensitivity CRP 
levels correlate with thrombosis risk in ET and PV [113]. 
Constitutional symptoms in MPN are similar to those 
observed in other inflammatory disorders. The influence 
of pro-inflammatory cytokines on bone marrow fibrosis 
has been demonstrated therefore showing a direct impact 
on the MPN phenotype [114]. These pro-inflammatory 
cytokines result from both mutant haematopoietic MPN 
clones and non–mutant haematopoietic cells as a direct 
result of JAK/STAT signalling driven by cytokine influ-
ences [111]. Therefore a self -reinforcing cycle of inflam-
mation is created. Recent investigation has shown that 
changes in the chromatin landscape by altered methyla-
tion and acetylation patterns at histone H3 lysine 4 and 
lysine 27, respectively links with increased expression of 
NF-KB signalling pathways driving associated inflamma-
tion [91].
RUX has demonstrated good efficacy in an anti-inflam-
matory role. It is efficacious in graft versus host disease 
and is under investigation in other immune mediated 
conditions [115]. A reduction in cytokine levels in MPN 
during RUX therapy is observed and the constitutional 
symptom burden is generally reduced. The reduction is 
spleen burden resulting from extramedullary haemat-
opoietic activity may also reflect a reduction in inflam-
mation. This anti-inflammatory effect can be augmented 
through the use of BET inhibitors to disrupt the epige-
netic enhancement of NF-KB signalling. In murine model 
of JAK2 V617F MF, the combination of RUX and BET 
inhibition resulted in significant reversal of bone marrow 
fibrosis and a reduction of disease burden [91]. Therefore 
targeted therapeutic manipulation of the pro-inflamma-
tory pathways appears to be an efficacious strategy which 
is worth further investigation in patients.
Future directions of therapy
The ground breaking efficacy of TKI monotherapy in 
CML has not been replicated in MPN through the use 
of targeted JAKi with RUX. Yet, the advances in our 
knowledge have revealed complexities in genetic land-
scape, epigenetic dysregulation, signaling cascades, DNA 
damage response and inflammatory pathways. Each 
of these abnormalities underlies the pathogenesis and 
impacts on the effectiveness of JAKi in these disorders. 
Augmentation of JAKi through concurrent therapeutic 
manipulation of alternative pathways is a key focus of 
current research. Clinical trials are underway to evalu-
ate the benefit of RUX alongside epigenetic modifiers, 
immunomodulatory drugs, small molecular inhibitors 
of PI3 K/AKT/mTOR and Interferon [116]. Understand-
ing how these combinations affect the burden of disease, 
level of bone marrow fibrosis and risk of progression is 
critical to establishing efficacy beyond the parameters 
demonstrated already by JAKi. As accurate personalized 
risk profiles become achievable based on genomic data, 
understanding how RUX fits the treatment for each of 
these individuals will be important. Development of JAKi 
with increased activity and/or allosteric inhibition along-
side agents with specificity for mutant JAK2 may be sig-
nificant in the coming years [117, 118]. Finally, effective 
eradication of the MPN stem cell niche will be required 
to bring about disease cure.
Conclusion
The advances in genomic and epigenetics over the 
last number of years have helped to reveal significant 
amounts of information regarding the pathogenesis of 
MPN. Rather than distinct disease entities, there is a 
complex evolving spectrum of pathology with common 
features and key differences. The role of constitutive 
activation of the JAK/STAT pathway is common across 
the spectrum whilst the role of co-operating mutations, 
epigenetic dysregulation, clonal evolution, responses to 
DNA damage, activation of cell signaling pathways and 
inflammatory activation varies resulting in differences 
in the observed MPN phenotype, progression of the dis-
ease and risk of thrombotic complications. This is allow-
ing a move away from simple grouping by phenotype in 
the clinic towards classification by increasingly towards 
a biological underpinnings of the phenotype. JAKi has 
demonstrated good efficacy in symptom relief but more 
limited impact on disease modification and there are 
concerns regarding the impact on clonal landscape that 
need careful evaluation. Understanding how JAKi affects 
and is affected by each of the key features of pathogenesis 
above is key to understanding how best to augment this 
therapy and establish an optimal therapeutic approach to 
this complex disease state.
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